• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

监测炎症性肠病中的硫嘌呤代谢物。

Monitoring thiopurine metabolites in inflammatory bowel disease.

作者信息

González-Lama Yago, Gisbert Javier P

机构信息

Gastroenterology and Hepatology Department, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain.

Gastroenterology Unit, Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Madrid, Spain.

出版信息

Frontline Gastroenterol. 2016 Oct;7(4):301-307. doi: 10.1136/flgastro-2015-100681. Epub 2016 Apr 7.

DOI:10.1136/flgastro-2015-100681
PMID:28839871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5369498/
Abstract

Thiopurines (azathioprine and mercaptopurine) are one of the immunosuppressive mainstays for the treatment of inflammatory bowel disease. In spite of its widespread use, thiopurine metabolism is still not fully understood, and a significant proportion of patients suffer toxicity or lack of efficacy. Different enzymatic pathways with individual variations constitute a pharmacogenetic model that seems to be suitable for monitoring and therapeutic intervention. This review is focused on current concepts and recent research that may help clinicians to rationally optimise thiopurine treatment in patients with inflammatory bowel disease.

摘要

硫嘌呤类药物（硫唑嘌呤和巯嘌呤）是治疗炎症性肠病的主要免疫抑制剂之一。尽管其广泛应用，但硫嘌呤的代谢仍未完全了解，且相当一部分患者会出现毒性反应或疗效不佳。具有个体差异的不同酶促途径构成了一个药物遗传学模型，似乎适用于监测和治疗干预。本综述聚焦于当前的概念和最新研究，这些可能有助于临床医生合理优化炎症性肠病患者的硫嘌呤治疗。

相似文献

1
Monitoring thiopurine metabolites in inflammatory bowel disease.监测炎症性肠病中的硫嘌呤代谢物。
Frontline Gastroenterol. 2016 Oct;7(4):301-307. doi: 10.1136/flgastro-2015-100681. Epub 2016 Apr 7.
2
Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.综述文章：药物遗传学在改善炎症性肠病硫嘌呤治疗中的益处。
Aliment Pharmacol Ther. 2012 Jan;35(1):15-36. doi: 10.1111/j.1365-2036.2011.04905.x. Epub 2011 Nov 2.
3
Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.硫唑嘌呤、6-巯基嘌呤在炎症性肠病中的应用：药理学、疗效及安全性
Clin Gastroenterol Hepatol. 2004 Sep;2(9):731-43. doi: 10.1016/s1542-3565(04)00344-1.
4
Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.炎症性肠病中硫唑嘌呤和6-巯基嘌呤的药物遗传学及代谢物监测
J Gastroenterol Hepatol. 2005 Aug;20(8):1149-57. doi: 10.1111/j.1440-1746.2005.03832.x.
5
Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.更新 2014：优化巯嘌呤和硫唑嘌呤以降低毒性并提高疗效的进展，用于治疗炎症性肠病。
Inflamm Bowel Dis. 2015 Feb;21(2):445-52. doi: 10.1097/MIB.0000000000000197.
6
Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring.通过药物基因组学和治疗药物监测新方法重新审视硫嘌呤类药物在炎症性肠病中的作用
Front Pharmacol. 2018 Oct 8;9:1107. doi: 10.3389/fphar.2018.01107. eCollection 2018.
7
Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.炎症性肠病中的硫嘌呤类药物：药物遗传学、治疗药物监测及临床建议
Dig Liver Dis. 2005 Apr;37(4):282-97. doi: 10.1016/j.dld.2004.09.029.
8
Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.硫嘌呤在炎症性肠病中的肝毒性：加用别嘌醇的作用。
Expert Opin Drug Saf. 2008 Sep;7(5):607-16. doi: 10.1517/14740338.7.5.607.
9
Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.炎症性肠病患者在与氨基水杨酸盐联合治疗期间硫嘌呤代谢产物的变化：N - 乙酰转移酶多态性的影响
World J Gastroenterol. 2015 Mar 28;21(12):3571-8. doi: 10.3748/wjg.v21.i12.3571.
10
How I treat my inflammatory bowel disease-patients with thiopurines?我如何用硫唑嘌呤治疗我的炎症性肠病患者？
World J Gastrointest Pharmacol Ther. 2016 Nov 6;7(4):524-530. doi: 10.4292/wjgpt.v7.i4.524.

引用本文的文献

1
Assessment of Azathioprine-Associated Lymphopenia Incidence Rates in Polish Children with Inflammatory Bowel Disease and Autoimmune Hepatitis: A Retrospective Study.波兰炎症性肠病和自身免疫性肝炎儿童中硫唑嘌呤相关淋巴细胞减少发生率的评估：一项回顾性研究
Children (Basel). 2025 Aug 20;12(8):1093. doi: 10.3390/children12081093.
2
A Simple, Rapid, and Cost-Effective PCR Procedure for Detection of Gene Variants in Vietnamese Patients with Acute Lymphoblastic Leukemia.一种用于检测越南急性淋巴细胞白血病患者基因变异的简单、快速且经济高效的聚合酶链反应方法。
J Lab Physicians. 2023 Jun 13;15(4):567-572. doi: 10.1055/s-0043-1768948. eCollection 2023 Dec.
3
Advances in Management of Intestinal Behçet's Disease: A Perspective From Gastroenterologists.肠道白塞病的管理进展：胃肠病学家的观点
J Rheum Dis. 2021 Jan 1;28(1):4-16. doi: 10.4078/jrd.2021.28.1.4.
4
A Validated HPLC-Diode Array Detection Method for Therapeutic Drug Monitoring of Thiopurines in Pediatric Patients: From Bench to Bedside.一种用于儿科患者硫嘌呤类药物治疗药物监测的经验证的高效液相色谱-二极管阵列检测方法：从实验室到临床应用
Metabolites. 2022 Nov 24;12(12):1173. doi: 10.3390/metabo12121173.
5
Usefulness of Measuring Thiopurine Metabolites in Children with Inflammatory Bowel Disease and Autoimmunological Hepatitis, Treated with Azathioprine.测量接受硫唑嘌呤治疗的炎症性肠病和自身免疫性肝炎患儿硫嘌呤代谢物的效用
Gastroenterol Res Pract. 2021 Jun 17;2021:9970019. doi: 10.1155/2021/9970019. eCollection 2021.
6
Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT.硫唑嘌呤类药物治疗溃疡性结肠炎：TPMT 中一种新的有害突变的鉴定。
Genes (Basel). 2020 Oct 16;11(10):1212. doi: 10.3390/genes11101212.
7
Thiopurine -methyltransferase genetic polymorphisms in adult patients with inflammatory bowel diseases in the Latvian population.拉脱维亚人群中成年炎症性肠病患者的硫嘌呤甲基转移酶基因多态性
Therap Adv Gastroenterol. 2020 Jul 14;13:1756284820937426. doi: 10.1177/1756284820937426. eCollection 2020.
8
Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics.炎症性肠病患者的硫嘌呤治疗：重点关注代谢和药物遗传学。
Dig Dis Sci. 2019 Sep;64(9):2395-2403. doi: 10.1007/s10620-019-05720-5. Epub 2019 Jul 9.
9
Azathioprine dosing and metabolite measurement in pediatric inflammatory bowel disease: does one size fit all?儿童炎症性肠病中硫唑嘌呤的剂量及代谢物测定：一种方法适用于所有人吗？
Ann Gastroenterol. 2019 Jul-Aug;32(4):387-391. doi: 10.20524/aog.2019.0381. Epub 2019 May 10.
10
Star Allele-Based Haplotyping versus Gene-Wise Variant Burden Scoring for Predicting 6-Mercaptopurine Intolerance in Pediatric Acute Lymphoblastic Leukemia Patients.基于星等位基因的单倍型分析与基因变异负担评分在预测儿童急性淋巴细胞白血病患者对6-巯基嘌呤不耐受中的比较
Front Pharmacol. 2019 Jun 11;10:654. doi: 10.3389/fphar.2019.00654. eCollection 2019.

本文引用的文献

1
Does lymphopenia or macrocytosis reflect 6-thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine?淋巴细胞减少或大细胞增多是否反映了接受硫唑嘌呤或6-巯基嘌呤治疗的炎症性肠病患者的6-硫鸟嘌呤水平？
Intern Med J. 2016 Apr;46(4):465-9. doi: 10.1111/imj.12915.
2
Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.鉴定 TPMT 变异患者并减少巯嘌呤剂量可降低炎症性肠病患者在硫唑嘌呤治疗期间的血液学事件。
Gastroenterology. 2015 Oct;149(4):907-17.e7. doi: 10.1053/j.gastro.2015.06.002. Epub 2015 Jun 11.
3
Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.常规确立的硫嘌呤代谢异常导致炎症性肠病患者早期治疗失败率极高。
Ther Drug Monit. 2015 Dec;37(6):797-804. doi: 10.1097/FTD.0000000000000213.
4
Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine.接受硫唑嘌呤治疗的儿科炎症性肠病患者中硫唑嘌呤剂量、6-硫鸟嘌呤核苷酸水平与治疗反应之间的关系
Inflamm Bowel Dis. 2015 May;21(5):1054-62. doi: 10.1097/MIB.0000000000000347.
5
Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.炎症性肠病患者在与氨基水杨酸盐联合治疗期间硫嘌呤代谢产物的变化：N - 乙酰转移酶多态性的影响
World J Gastroenterol. 2015 Mar 28;21(12):3571-8. doi: 10.3748/wjg.v21.i12.3571.
6
Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.在接受联合治疗的炎症性肠病患者中，6-硫代鸟嘌呤核苷酸的浓度与英夫利昔单抗的谷浓度相关。
Clin Gastroenterol Hepatol. 2015 Jun;13(6):1118-24.e3. doi: 10.1016/j.cgh.2014.12.026. Epub 2015 Jan 3.
7
Is less more: does leukopenia predict remission in patients with inflammatory bowel disease receiving thiopurine treatment?少即是多：白细胞减少症能否预测接受硫唑嘌呤治疗的炎症性肠病患者的缓解情况？
Dig Dis Sci. 2015 Jan;60(1):4-6. doi: 10.1007/s10620-014-3481-z.
8
Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.更新 2014：优化巯嘌呤和硫唑嘌呤以降低毒性并提高疗效的进展，用于治疗炎症性肠病。
Inflamm Bowel Dis. 2015 Feb;21(2):445-52. doi: 10.1097/MIB.0000000000000197.
9
Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBD.血液学指标可作为监测 IBD 患者硫嘌呤治疗的替代标志物。
Dig Dis Sci. 2015 Feb;60(2):478-84. doi: 10.1007/s10620-014-3362-5. Epub 2014 Sep 19.
10
Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.硫唑嘌呤和6-巯基嘌呤用于维持克罗恩病手术诱导的缓解状态
Cochrane Database Syst Rev. 2014 Aug 1;2014(8):CD010233. doi: 10.1002/14651858.CD010233.pub2.